Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Want to see JANX full AI Analyst Report?
Top Page
Janux Therapeutics Inc
(NASDAQ:JANX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$15.00
▼(-5.18% Downside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by weak financial performance (widening losses and cash burn risk) and a weak longer-term technical trend. These are partially offset by a strong, low-leverage balance sheet and a notable positive corporate event (the BMS collaboration) that could enhance long-term prospects.
Positive Factors
Proprietary tumor-activated therapeutic platforms
Janux's platform focus on tumor-activated engagers and ADCs targets better tumor selectivity and tolerability, a durable competitive angle in solid tumors. Platform-level assets can create multiple clinic-stage candidates and licensing opportunities, supporting long-term value creation.
Negative Factors
Minimal product revenue; no commercial sales
With no approved products and only modest revenue, Janux remains structurally pre-revenue and dependent on financing and collaborations. Lack of recurring product sales prolongs funding needs and makes long-term sustainability contingent on successful trials or partnership payments.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary tumor-activated therapeutic platforms
Janux's platform focus on tumor-activated engagers and ADCs targets better tumor selectivity and tolerability, a durable competitive angle in solid tumors. Platform-level assets can create multiple clinic-stage candidates and licensing opportunities, supporting long-term value creation.
Read all positive factors
Janux Therapeutics Inc (JANX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$872.33M
Dividend YieldN/A
Average Volume (3M)1.07M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-5.55%
EPS Growth-43.27%
CountryUS
Employees91
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.83
Shares Outstanding60,831,657
10 Day Avg. Volume853,149
30 Day Avg. Volume1,068,909
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue47.10
Enterprise Value/Gross Profit99.79
Enterprise Value/Ebitda-6.28
Forecast
1Y Price Target
$43.15Price Target Upside172.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-2.44
Revenue Forecast (FY)$17.25M
Janux Therapeutics Inc Business Overview & Revenue Model
Company Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates tha...
How the Company Makes Money
Janux Therapeutics does not sell approved commercial products and therefore does not generate product sales revenue. The company primarily funds operations through (1) capital raised in the public markets and other financing activities (e.g., equi...
Janux Therapeutics Inc Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
83
Very Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.00M | 10.59M | 8.08M | 8.61M | 3.64M |
| Gross Profit | 7.97M | 8.53M | 6.13M | 7.77M | 3.64M |
| EBITDA | -111.60M | -96.79M | -71.02M | -66.25M | -32.82M |
| Net Income | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M |
Balance Sheet | |||||
| Total Assets | 1.01B | 1.06B | 380.41M | 364.01M | 379.82M |
| Cash, Cash Equivalents and Short-Term Investments | 966.57M | 1.03B | 344.03M | 327.02M | 374.96M |
| Total Debt | 22.14M | 23.02M | 24.54M | 25.30M | 194.00K |
| Total Liabilities | 50.70M | 38.73M | 36.06M | 43.27M | 13.50M |
| Stockholders Equity | 956.82M | 1.02B | 344.35M | 320.74M | 366.33M |
Cash Flow | |||||
| Free Cash Flow | -83.28M | -44.17M | -52.42M | -49.37M | -18.46M |
| Operating Cash Flow | -82.23M | -43.81M | -50.58M | -42.92M | -16.98M |
| Investing Cash Flow | -300.98M | -258.02M | -41.19M | 58.27M | -340.96M |
| Financing Cash Flow | 4.95M | 713.24M | 59.55M | 500.00K | 386.52M |
Janux Therapeutics Inc Technical Analysis
Positive
15.82
Price Trends
13.90
Positive
15.28
Positive
20.28
Negative
Market Momentum
0.40
Negative
68.38
Neutral
78.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Positive. The current price of 15.82 is above the 20-day moving average (MA) of 14.42, above the 50-day MA of 13.90, and below the 200-day MA of 20.28, indicating a neutral trend. The MACD of 0.40 indicates Negative momentum. The RSI at 68.38 is Neutral, neither overbought nor oversold. The STOCH value of 78.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JANX.
Janux Therapeutics Inc Risk Analysis
Janux Therapeutics Inc disclosed 79 risk factors in its most recent earnings report. Janux Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Janux Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $3.28B | -12.72 | -31.97% | ― | ― | -12.95% | |
57 Neutral | $1.89B | -7.95 | -70.76% | ― | ― | -25.27% | |
56 Neutral | $2.52B | -10.86 | -59.72% | ― | ― | -70.12% | |
54 Neutral | $1.37B | -5.48 | -58.44% | ― | 23359.93% | -0.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $872.33M | -7.53 | -11.55% | ― | -5.55% | -43.27% | |
44 Neutral | $1.45B | -1.64 | -688.89% | ― | ― | 25.88% |
* Healthcare Sector Average
JANX
Janux Therapeutics Inc
14.34
-15.45
-51.86%
VRDN
Viridian Therapeutics
13.42
0.30
2.29%
PHVS
Pharvaris
29.44
10.78
57.77%
EWTX
Edgewise Therapeutics
30.61
14.07
85.07%
VERA
Vera Therapeutics
35.20
9.67
37.88%
BHVN
Biohaven Ltd.
9.63
-12.99
-57.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.